Seattle Genetics, Inc.  

(Public, NASDAQ:SGEN)   Watch this stock  
Find more results for Seattle Genetics Inc´┐Ż
+1.01 (2.45%)
Aug 28 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 40.97 - 42.25
52 week 30.05 - 52.33
Open 40.97
Vol / Avg. 537,047.00/869,397.00
Mkt cap 5.17B
P/E     -
Div/yield     -
EPS -0.90
Shares 125.34M
Beta 1.56
Inst. own 103%
Oct 28, 2015
Q3 2015 Seattle Genetics Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jul 30, 2015
Q2 2015 Seattle Genetics Inc Earnings Call - Webcast
Jul 30, 2015
Q2 2015 Seattle Genetics Inc Earnings Release
Jun 1, 2015
Seattle Genetics Inc at Jefferies Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -61.61% -26.55%
Operating margin -61.69% -26.98%
EBITD margin - -22.62%
Return on average assets -44.61% -16.15%
Return on average equity -97.98% -34.53%
Employees 657 -
CDP Score - -


21823 30th Dr SE
BOTHELL, WA 98021-3907
United States - Map
+1-425-5274000 (Phone)
+1-425-5274001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company's marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC) comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing its technology. In addition to ADCETRIS, the Company's pipeline includes six clinical-stage ADC programs consisting of SGN-CD33A, SGN-CD19A, SGN-LIV1A, SGN-CD70A, ASG-22ME, and ASG-15ME, and SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology. In addition, it has multiple preclinical and research-stage programs that employ its technologies. Its technologies include ADC technology and Seattle Genetics' sugar-engineered antibody (SEA) technology.

Officers and directors

Clay B. Siegall Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 54
Bio & Compensation  - Reuters
Todd E Simpson Chief Financial Officer
Age: 54
Bio & Compensation  - Reuters
Eric L. Dobmeier Chief Operating Officer, Corporate Secretary
Age: 46
Bio & Compensation  - Reuters
Jean I. Liu J.D. Executive Vice President - Legal Affairs, General Counsel, Corporate Secretary
Age: 47
Bio & Compensation  - Reuters
Jonathan Drachman M.D. Chief Medical Officer and Executive Vice President, Research and Development
Age: 53
Bio & Compensation  - Reuters
Vaughn B. Himes Executive Vice President - Technical Operations, Process Sciences
Age: 54
Bio & Compensation  - Reuters
Felix J. Baker Ph.D. Lead Independent Director
Age: 46
Bio & Compensation  - Reuters
John A. Orwin Director
Age: 50
Bio & Compensation  - Reuters
Srinivas Akkaraju M.D., Ph.D. Independent Director
Age: 47
Bio & Compensation  - Reuters
David W. Gryska Independent Director
Age: 59
Bio & Compensation  - Reuters